New Scientific Publication Suggests Pressure BioSciences PCT
Platform Could Play Significant Role
in Personalized/Precision Medicine
Key Protein Scientists Report Unique Benefits of the PCT
Platform in the Analysis of Critical Samples, Such as Cancer
Tissue Biopsies and Stem Cells
South Easton, MA, September 1, 2015 Pressure BioSciences, Inc.
(OTCQB:
PBIO) (PBI and the Company), a leader in the development and
sale of broadly enabling, pressure cycling technology (PCT)-based
sample preparation solutions to the worldwide life sciences
industry, today announced the publication of an article with
findings that suggest the Companys PCT Platform could play a
significant role in expanding the reach of personalized/precision
medicine. This role is based on PCTs unique ability to help reveal
and analyze thousands of proteins in small diagnostic samples, such
as tissue biopsies extracted in tiny needles from cancer patients,
compared to current methods that analyze only hundreds of proteins
at best. This significant increase in analyzed proteins could
result in a better understanding of the patients cancer, disease
progression, response to therapy, and treatment options.
Dr. Nate Lawrence, Vice President of Marketing and Sales for
PBI, said: The study published by Dr. Shiying Shao and her
colleagues showed PCTs ability to help analyze far more proteins in
small samples than current methods. The study also highlighted the
efficiency, consistency, and accuracy of the PCT platform across
many different clinical and research sample types. We are aware of
similar data recently generated by other researchers. It is
therefore not surprising to us that interest in our PCT product
line has grown rapidly over the past year. We believe this
increased interest is partly responsible for our guidance that
revenue in the third quarter of 2015 will exceed half a million
dollars for the first time ever and that revenue for the year 2015
will be the highest annual revenue in the history of PBI.
Dr. Vera Gross, Senior Scientist in R&D at PBI, said: The
analysis of proteins can give valuable information related to a
disease or disorder, which can then be used to help prevent,
control, and/or cure the condition. Today, the gold standard
research tool for protein analysis is mass spectrometry (MS).
Unfortunately, while MS is very sensitive, it requires a larger
amount of starting material (cells or tissue) than is sometimes
available. This severely limits its use in the clinical and
research fields. Many important samples, especially ones like
cancer tissue biopsies and stem cells, have historically been too
small for efficient MS analysis, thus limiting their usefulness as
either diagnostic or research tools.
Dr. Shiying Shao, lead author of the publication, commented: We
recently developed and reported on a method called PCT-SWATH that
combines PCT with AB Sciexs SWATH-MS. This method results in highly
reproducible mass spectrometry analyses, even in samples that were
previously too small to be analyzed by MS. Since it is vital to
obtain maximum information from these critically important small
starting materials, we evaluated the minimal amount of tissue and
cells that can be analyzed by PCT-SWATH. The results were
impressive: we found PCT-SWATH could consistently analyze small
samples that previously could not be analyzed by MS, like cancer
tissue biopsies, flow cytometry-sorted blood cells,
genetically-manipulated cells, primary cells that cannot be
substantially expanded, and stem cells.
Dr. Tiannan Guo, co-author of the publication, said: In our
study, we found that PCT-SWATH could efficiently and reproducibly
measure thousands of proteins from minute and diverse tissue biopsy
samples. It is estimated that there are as many as 5 million small
needle tissue biopsies performed each year. We believe that
MS-based analyses can identify targets for cancer therapy in these
biopsy samples. We further believe that MS-based analyses of these
samples can help give the physician more and better treatment
options, possibly ruling out ineffective therapies or encouraging
more productive, less deleterious chemotherapies.
Mr. Richard T. Schumacher, President and CEO of PBI, commented:
We look forward to the continued growth in interest in our PCT
product line. We also look forward to the completion of our current
PIPE financing, since part of the proceeds will go to significantly
expand the size and capabilities of our current sales and marketing
team. This we believe will allow us to take better advantage of the
very exciting opportunity with PCT-SWATH.
Link to the Publication in the Journal Proteomics
The paper was published in the respected, on-line journal
Proteomics. Lead authors are Dr. Shiying Shao of the Tongji
Hospital, Huazhong University of Science and Technology (Wuhan, PR
China) and Dr. Tiannan Guo of the Institute of Molecular Systems
Biology, ETH Zurich (Zurich, Switzerland). The publication,
entitled Minimal sample requirement for highly multiplexed protein
quantification in cell lines and tissues by PCT-SWATH mass
spectrometry, is available on-line and can be found via the
following link: http://onlinelibrary.wiley.com/doi/10.1002/pmic.201500161/abstract
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) (OTCQB:
PBIO) develops, markets, and sells proprietary laboratory
instrumentation and associated consumables to the estimated $6
billion life sciences sample preparation market. Our products are
based on the unique properties of both constant (i.e., static) and
alternating (i.e., pressure cycling technology, or PCT) hydrostatic
pressure. PCT is a patented enabling technology platform that uses
alternating cycles of hydrostatic pressure between ambient and
ultra-high levels to safely and reproducibly control bio-molecular
interactions. To date, we have installed over 250 PCT systems in
approximately 160 sites worldwide. There are over 100 publications
citing the advantages of the PCT platform over competitive methods,
many from key opinion leaders. Our primary application development
and sales efforts are in the biomarker discovery and forensics
areas. Customers also use our products in other areas, such as drug
discovery & design, bio-therapeutics characterization, soil
& plant biology, vaccine development, histology, and forensic
applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's
intentions, hopes, beliefs, expectations, or predictions of the
future are "forward-looking'' statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
are based upon the Company's current expectations, forecasts, and
assumptions that are subject to risks, uncertainties, and other
factors that could cause actual outcomes and results to differ
materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include,
but are not limited to, the risks and uncertainties discussed under
the heading "Risk Factors" in the Company's Annual Report on Form
10-K for the year ended December 31, 2014, and other reports filed
by the Company from time to time with the SEC. The Company
undertakes no obligation to update any of the information included
in this release, except as otherwise required by law.
For more information about PBI and this press release, please
click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Twitter | LinkedIn | YouTube | Google+ | Facebook
Richard T. Schumacher, President & CEO Pressure BioSciences,
Inc.
Nathan P. Lawrence, Ph.D. VP of Marketing and Sales (508)
230-1828 (T)